Shanghai Fosun Pharmaceutical (Group) , Ltd. Receivables

The latest receivables for SFOSF is $9.8B as of June 2026. That compares with $10B in the prior-year period — down 1.3% year over year. Investors often review this figure alongside Shanghai Fosun Pharmaceutical (Group) , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, SFOSF's receivables moved from $10B to $9.8B — a 1.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Shanghai Fosun Pharmaceutical (Group) , Ltd.'s operating scale or balance-sheet position.

A receivables figure of $9.8B for SFOSF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting SFOSF's receivables ($9.8B), review year-over-year change from $10B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.